Prionlar ve Yavaş Virüs Enfeksiyonları
Özet
Prionlar, insanlar ve memelilerde uzun kuluçka sürelerine sahip, nörodejeneratif hastalıklara yol açan, nükleik asit içermeyen protein yapısındaki bulaşıcı ajanlardır. Başlangıçta "yavaş virüs" olarak tanımlanan bu etkenler, radyasyona dirençli yapılarıyla bilinir ve hücresel prion proteinlerinin (PrP-C) patolojik forma (PrP-Sc) dönüşümüyle beyinde amiloid birikimi ve hücre kaybına neden olur. Kuru ve Scrapie gibi hastalıklar bu grubun tipik örneklerini oluştururken, patogenezde retiküloendotelyal sistem ve aksonal yolların kritik rol oynadığı kabul edilmektedir.
Prions are infectious proteinaceous agents lacking nucleic acids that cause progressive neurodegenerative diseases in humans and other mammals after long incubation periods. Originally misidentified as "slow viruses," these agents are characterized by their resistance to physical and chemical treatments, where cellular prion proteins (PrP-C) misfold into a pathological form (PrP-Sc) that accumulates in the brain. This process leads to significant vacuolization, neuronal loss, and amyloid deposits, with conditions like Kuru and Scrapie serving as hallmark examples. The spread of these agents typically involves the reticuloendothelial system and axonal pathways, resulting in severe clinical deterioration.
Referanslar
Schneider K, Fangerau H, Michaelsen B, et al. The early history of the transmissible spongiform encephalopathies exemplified by scrapie. Brain Res Bull. 2008;77:343– 355.
Cuille J, Chelle P. Experimental transmission of trembling to the goat. Comptes Rendus Académie Sci. 1939;208:1058–1060.
Alper T, Haig DA, Clarke MC. The exceptionally small size of the scrapie agent. Biochem Biophys Res Commun. 1966;22:278–284.
Gajdusek DC, Gibbs CJ, Alpers M. Experimental transmission of a Kuru-like syndrome to chimpanzees. Nature. 1966;209:794–796.
Hadlow W. Scrapie and kuru. Lancet. 1959;274:289–290.
Prusiner SB, Groth DF, Cochran SP, et al. Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry Mosc. 1980;19:4883–4891.
Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136–144. 8. Oesch B, Westaway D, Wälchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell. 1985;40:735–746.
Stahl N, Borchelt DR, Hsiao K, et al. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell. 1987;51:229–240.
Manson J, West JD, Thomson V, et al. The prion protein gene: a role in mouse embryogenesis? Development. 1992;115:117–122.
Moser M, Colello RJ, Pott U, et al. Developmental expression of the prion protein gene in glial cells. Neuron. 1995;14:509–517.
Linden R, Martins VR, Prado MAM, et al. Physiology of the prion protein. Physiol Rev. 2008;88:673–728.
Laurén J, Gimbel DA, Nygaard HB, et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128–1132.
Diaz-Espinoza R, Soto C. High-resolution structure of infectious prion protein: the final frontier. Nat Struct Mol Biol. 2012;19:370–377.
Singh J, Udgaonkar JB. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: current Understanding and Its Implications. Biochemistry Mosc. 2015;54:4431–4442.
Silveira JR, Raymond GJ, Hughson AG, et al. The most infectious prion protein particles. Nature. 2005;437:257–261.
Deleault NR, Harris BT, Rees JR, et al. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA. 2007;104:9741–9746.
Scott M, Foster D, Mirenda C, et al. Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell. 1989;59:847–857.
Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318:930–936.
Safar J, Wille H, Itri V, et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med. 1998;4:1157–1165.
Ushiki-Kaku Y, Shimizu Y, Tabeta N, et al. Heterogeneity of abnormal prion protein (PrP(Sc)) in murine scrapie prions determined by PrP(Sc)-specific monoclonal antibodies. J Vet Med Sci. 2014;76:285–288.
Prinz M, Huber G, Macpherson AJS, et al. Oral prion infection requires normal numbers of Peyer’s patches but not of enteric lymphocytes. Am J Pathol. 2003;162:1103–1111.
Chiocchetti R, Mazzuoli G, Albanese V, et al. Anatomical evidence for ileal Peyer’s patches innervation by enteric nervous system: a potential route for prion neuroinvasion? Cell Tissue Res. 2008;332:185–194.
Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science. 2012;336:1511–1513.
Patrick J. Bosque, Kenneth L.Tyler. Prions and Prion Disease of Central Nervous System (Transmissible Neurodegenerative Diseases). İnfectious Diseases and Their Etiologic Agents; Chapter 179, 2288-2300.
Puoti G, Bizzi A, Forloni G, etal. Sporadic human prion diseases:molecular insights and diagnosis.Lancet Neurol 2012;11:618.
Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology. 2005;64:1586–1591.
Heinemann U, Krasnianski A, Meissner B, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain. 2007;130(Pt 5):1350–1359.
Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology. 1999;52:1757–1763.
Zou W-Q, Puoti G, Xiao X, et al. Variably proteasesensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol. 2010;68:162–172.
Zou W-Q, Gambetti P, Xiao X, et al. Prions in variably protease-sensitive prionopathy: an update. Pathogens. 2013;2:457–471.
Head MW, Yull HM, Ritchie DL, et al. Variably protease-sensitive prionopathy in the UK: a retrospective review 1991-2008. Brain. 2013;136(Pt 4):1102–1115.
Heidenhain A. Klinische und anatomische Untersuchungen Über eine eigenartige Erkrankung des Zentralnervensystems im Praesenium. Z Ges Neurol Psychiat. 1929;118:49–114.
Brownell B, Oppenheimer DR. An ataxic form of subacute presinle polioencephalopathy (Creutzfeldt-Jakob disease). J Neurol Neurosurg Psychiatry. 1965;28:350–361.
Stern K. Severe dementia associated with bilateral symmetrical degeneration of the thalamus. Brain. 1939;62:157–171.
Garcin R, Brion S, Khochneviss A. Le syndrome de Creutzfeldt-Jakob et les syndromes corticostries du presenium (a l’occasion de 5 observations anatomocliniques). Rev Neurol (Paris). 1963;109:419–441.
Wall CA, Rummans TA, Aksamit AJ, et al. Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25-year analysis. J Neuropsychiatry Clin Neurosci. 2005;17:489–495.
Macleod M-A, Stewart GE, Zeidler M, et al. Sensory features of variant Creutzfeldt-Jakob disease. J Neurol. 2002;249:706–711.
Niewiadomska M, Kulczycki J, Wochnik-Dyjas D, et al. Impairment of the peripheral nervous system in Creutzfeldt-Jakob disease. Arch Neurol. 2002;59:1430–1436.
Kovács T, Arányi Z, Szirmai I, et al. Creutzfeldt-Jakob disease with amyotrophy and demyelinating polyneuropathy. Arch Neurol. 2002;59:1811–1814.
Worrall BB, Rowland LP, Chin SS, et al. Amyotrophy in prion diseases. Arch Neurol. 2000;57:33–38.
Nagasaka K, Ohta E, Nagasaka T, et al. Rhythmic pupillary oscillation in Creutzfeldt-Jakob disease associated with the Glu/Lys mutation of prion protein codon 200. Mov Disord. 2010;25:111–116.
Huber FM, Bour F, Sazdovitch V, et al. Creutzfeldt-Jakob disease with slow progression. A mimickry of progressive supranuclear palsy. Bull Soc Sci Med Grand Duche Luxemb. 2007;2:125–130.
Litzroth A, Cras P, De Vil B, Quoilin S. Overview and evaluation of15 years of Creutzfeldt-Jakob disease surveillance in Belgium,1998–2012. BMC Neurol 2015; 15: 250.
Ali A, Abbas M, Ahmed S, Ejaz K. Creutzfeldt-Jakob Disease (CJD)rare stroke mimic. Cerebrovasc Dis 2015; 39: 147.
Hirst CL. Sporadic Creutzfeldt-Jakob disease presenting as a stroke mimic. Br J Hosp Med 2011; 72: 590–91.
Hanumanthu R, Alchaki A, Nyaboga A, et al. An unusual case of sporadic Creutzfeld-Jacob disease presenting as acute neuropathy. Mov Disord 2017; 32: 563–64.
Karatas H, Dericioglu N, Kursun O, Saygi S. Creutzfeldt-Jakob disease presenting as hyperparathyroidism and generalized tonic status epilepticus. Clin EEG Neurosci 2007; 38: 203–06.
Kher M, Rao MY, Acharya PT, Mahadevan A, Shankar SK. Heidenhain variant of Creutzfeldt-Jakob disease: An autopsy study from India. Ann Indian Acad Neurol 2009; 12: 48–51.
Neville JL, Fichtenbaum C. Rapidly progressive dementia: sometimes it is a zebra. J Gen Intern Med 2012; 27: S508.
Pachalska M, Kurzbauer H, Formińska-Kapuścik M, Urbanik A, Bierzyńska-Macyszyn G, Właszczuk P. Atypical features of dementia in a patient with Creutzfeldt-Jakob disease. Med Sci Monit 2007; 13: CS9–19.
Patrawala S, Soltani M, Zulauf M. A rare case of ataxia and rapidly progressing dementia. J Gen Intern Med 2014; 29: S280–81.
Krystina C, Abbas A, Hall A, Khadjooi K, Abasaeed-Elhag R, Rostami K. Sporadic CJD presenting with aphasia diagnosed in medical admissions unit. Eur J Intern Med 2011; 22: S111.
Sann AA, Zaw MM, Choie TL. Creutzfeldt-Jakob disease presenting predominantly with movement disorder: a case report. Mov Disord 2016; 31: S577–78.
Spielmeyer W. Die histopathologische Forschung in der Psychiatrie. Klin Wochenschr. 1922:1817–1819.
Jakob A. Über eine der multiplen Sklerose klinisch nahestehende Erkrankung des Zentralnervensystems (spastische Pseudosklerose) mit bemerkenswertem anatomischem Befunde. Mitteilung eines vier ten Falles. Med Klin. 1921;17:372–376.
The National CJD Research & Surveillance Unit. 25th Annual Report. Creutzfeldt-Jakob disease surveillance in the UK; 2017. http://www.cjd.ed.ac.uk/surveillance/ data-and-reports. Accessed November 22, 2017.
Klug GM, Wand H, Boyd A, et al. Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain 2009; 132: 493–501.
Klug GM, Wand H, Simpson M, et al. Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry 2013; 84: 1372–77.
Lugaresi E, Medori R, Montagna P, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med. 1986;315:997–1003.
Manetto V, Medori R, Cortelli P, et al. Fatal familial insomnia: clinical and pathologic study of five new cases. Neurology. 1992;42:312–319.
Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med. 1992;326:444–449.
Montagna P, Gambetti P, Cortelli P, et al. Familial and sporadic fatal insomnia. Lancet Neurol. 2003;2:167–176.perties. Emerg Infect Dis. 2014;20:1969–1979.
Kovács GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet. 2005;118:166–174.
Zarranz JJ, Digon A, Atarés B, et al. Phenotypic variability in familial prion diseases due to the D178N mutation. J Neurol Neurosurg Psychiatry. 2005;76:1491–1496.
Krasnianski A, Bartl M, Sanchez Juan PJ, et al. Fatal familial insomnia: clinical features and early identification. Ann Neurol. 2008;63:658–661.
Landolt H-P, Glatzel M, Blättler T, et al. Sleep-wake disturbances in sporadic Creutzfeldt-Jakob disease. Neurology. 2006;66:1418–1424. 72. Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322-9.
Tagliavini F, Prelli F, Ghiso J, et al. Amyloid protein of Gerstmann-Sträussler-Scheinker disease (Indiana kindred) is an 11 kd fragment of prion protein with an N-terminal glycine at codon 58. EMBO J. 1991;10:513–519.
Giaccone G, Verga L, Bugiani O, et al. Prion protein preamyloid and amyloid deposits in Gerstmann Sträussler-Scheinker disease, Indiana kindred. Proc Natl Acad Sci USA. 1992;89:9349–9353.
Collins S, McLean CA, Masters CL. GerstmannSträussler-Scheinker syndrome,fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci. 2001;8:387–397.
Liberski PP, Bratosiewicz J, Waliś A, et al. A special report I. Prion protein (PrP)–amyloid plaques in the transmissible spongiform encephalopathies, or prion diseases revisited. Folia Neuropathol. 2001;39:217–235.
Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322-9.
Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. N Engl J Med. 1957;257:974–978.
Huillard d’Aignaux JN, Cousens SN, Maccario J, et al. The incubation period of kuru. Epidemiol Camb Mass. 2002;13:402–408.
Whitfield JT, Pako WH, Collinge J, et al. Cultural factors that affected the spatial and temporal epidemiology of kuru. R Soc Open Sci. 2017;4:160789.
McLean CA. Review. The neuropathology of kuru and variant Creutzfeldt-Jakob disease. Philos Trans R Soc Lond B Biol Sci. 2008;363:3685–3687.
Collinge J, Whitfield J, McKintosh E, et al. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci. 2008;363:3725–3739.
Britton TC, al-Sarraj S, Shaw C, et al. Sporadic Creutzfeldt-Jakob disease in a 16-year-old in the UK. Lancet. 1995;346:1155.
Wroe SJ, Pal S, Siddique D, et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet. 2006;368:2061–2067.
Maheshwari A, Fischer M, Gambetti P, et al. Recent US case of variant Creutzfeldt-Jakob disease—global implications. Emerg Infect Dis. 2015;21:750–759.
Latest CJD Figures. May 2017. http://www.cjd.ed.ac.uk/ data-and-reports/latest-cjd-figures. Accessed June 3, 2017.
Boëlle P-Y, Cesbron J-Y, Valleron A-J. Epidemiological evidence of higher susceptibility to vCJD in the young. BMC Infect Dis. 2004;4:26.
Boesenberg C, Schulz-Schaeffer WJ, Meissner B, et al. Clinical course in young patients with sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2005;58:533–543.
Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127(Pt 10):2348–2359.
Spencer MD, Knight RSG, Will RG. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. BMJ. 2002;324:1479–1482.
Zeidler M, Johnstone EC, Bamber RW, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997;350:908–910.
Urwin PJM, Mackenzie JM, Llewelyn CA, et al. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang. 2016;110:310–316.
Brown P, Brandel J-P, Sato T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis. 2012;18:901–907.
Defebvre L, Destée A, Caron J, et al. Creutzfeldt-Jakob disease after an embolization of intercostal arteries with cadaveric dura mater suggesting a systemic transmission of the prion agent. Neurology. 1997;48:1470–1471.
Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921–925.
Hill AF, Joiner S, Wadsworth JDF, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 2003;126(Pt 6):1333–1346.
Biacabe A-G, Morignat E, Vulin J, et al. Atypical bovine spongiform encephalopathies, France, 2001-2007. Emerg Infect Dis. 2008;14:298–300.
Béringue V, Bencsik A, Le Dur A, et al. Isolation from cattle of a prion strain distinct from that causing bovine spongiform encephalopathy. PLoS Pathog. 2006;2:e112.
Bui E, Ehrensperger E, Sahlas DJ, et al. Inflammatory cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Can J Neurol Sci. 2008;35:625–629.
Macfarlane RG, Wroe SJ, Collinge J, et al. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry. 2007;78:664–670.
Zanusso G, Monaco S, Pocchiari M, et al. Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease. Nat Rev Neurol. 2016;12:325–333.
Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81:79–92.
Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79:1499–1506.
Fragoso DC, Gonçalves Filho AL da M, Pacheco FT, et al. Imaging of Creutzfeldt-Jakob disease: imaging patterns and their differential diagnosis. Radiographics. 2017;37:234–257.
Tschampa HJ, Kallenberg K, Urbach H, et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain. 2005;128(Pt 9):2026–2033.
Collie DA, Summers DM, Sellar RJ, et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol. 2003;24:1560–1569.
Aguglia U, Farnarier G, Tinuper P, et al. Subacute spongiform encephalopathy with periodic paroxysmal activities: clinical evolution and serial EEG findings in 20 cases. ClinElectroencephalogr. 1987;18:147–158.
Steinhoff BJ, Räcker S, Herrendorf G, et al. Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol. 1996;53:162–166.
Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358: 171–80.
Bell JE, Gentleman SM, Ironside JW, et al. Prion protein immunocytochemistry–UK five centre consensus report. Neuropathol Appl Neurobiol. 1997;23:26–35.
Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46:224–233.
Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain. 2006;129(Pt 9):2241–2265.
Aguzzi A, Lakkaraju AKK, Frontzek K. Toward therapy of human prion diseases. Annu Rev Pharmacol Toxicol. 2018;58:331–351.
